Mutation of p53 in head and neck squamous cell carcinoma correlates with Bcl‐2 expression and increased susceptibility to cisplatin‐induced apoptosis
- 9 July 2004
- journal article
- review article
- Published by Wiley in Head & Neck
- Vol. 26 (10) , 870-877
- https://doi.org/10.1002/hed.20029
Abstract
Background. The p53 protein, a well-known tumor suppressor that functions primarily as a transcription factor, initiates cell cycle arrest and apoptosis after genotoxic stress. The antiapoptotic regulator Bcl-2 is a downstream modulator of p53-induced apoptosis. Loss of function of the p53 tumor suppressor through mutation is an important event that contributes to cellular transformation. Mutation of p53 is one of the most common genetic alterations in squamous cell carcinomas of the head and neck (SCCHN). We hypothesized that p53 mutation is associated with Bcl-2 expression and susceptibility to apoptosis in SCCHN. Methods. Exons 5 to 8 of the p53 gene were sequenced in 22 SCCHN tumor samples and correlated with the Bcl-2 expression and apoptosis rates in these tumors. In addition, a Bcl-2–expressing SCCHN cell line, UMSCC74B, was stably transfected with a temperature-sensitive mutant p53 construct, and Bcl-2 expression levels were examined at the mutant and the wild-type temperatures. Results. Bcl-2 expression was inversely correlated with wild-type p53 status in SCCHN tumors (p = .05). Furthermore, there was a modest increase (1.7-fold) in apoptosis in the wild-type p53 tumors compared with mutant p53 SCCHN. Immunoblotting of UMSCC74B cells stably transfected with the temperature-sensitive mutant p53 construct demonstrated that shifting these cells to the mutant p53 temperature (39.5°C) resulted in decreased expression of Bcl-2 compared with levels in cells grown at the wild-type p53 temperature (32.5°C). Further investigation showed that SCCHN cells expressing predominantly mutant p53 and decreased Bcl-2 were more susceptible to cisplatin-induced apoptosis than vector-transfected controls (p < .0001). Conclusions. These results suggest that p53 mutation directly modulates Bcl-2 expression and therefore susceptibility to chemotherapy-induced apoptosis in SCCHN cells in vitro. © 2004 Wiley Periodicals, Inc. Head Neck 26: 870–877, 2004Keywords
This publication has 27 references indexed in Scilit:
- Mechanisms of ApoptosisThe American Journal of Pathology, 2000
- De novo programmed cell death in oral cancerHistopathology, 1999
- p53 Expression: Predicting Recurrence and Second Primary Tumors in Head and Neck Squamous Cell CarcinomaJNCI Journal of the National Cancer Institute, 1996
- A novel form of Epstein-Barr virus latency in normal B cells in vivoCell, 1995
- Tumor suppressor p53 is a direct transcriptional activator of the human bax geneCell, 1995
- p53-Dependent apoptosis suppresses tumor growth and progression in vivoCell, 1994
- bcl-2 Protein in Non-Small-Cell Lung CarcinomaNew England Journal of Medicine, 1993
- Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programed cell deathCell, 1993
- Suppression of human nasopharyngeal carcinoma cell growth in nude mice by the wild-type p53 geneZeitschrift für Krebsforschung und Klinische Onkologie, 1992
- Cellular localization and cell cycle regulation by a temperature-sensitive p53 protein.Genes & Development, 1991